NCT05729399View on ClinicalTrials.gov

Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

September 14, 2022

Primary Completion Date

May 1, 2025

Study Completion Date

May 1, 2025

Conditions
Solid Tumor
Interventions
BIOLOGICAL

GT201

Autologous tumor infiltrating lymphocyte injection

Trial Locations (4)

215006

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

450000

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

Unknown

RECRUITING

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

Sponsors

Lead Sponsor

Grit Biotechnology
All Listed Sponsors
lead

Grit Biotechnology

INDUSTRY

NCT05729399 - Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors | Biotech Hunter | Biotech Hunter